Evidence map›Paper›PMID 42883892›Full record

ReviewInternational journal of molecular sciences2026

Advances in Treatment of Refractory Advanced and Recurrent Cervical Adenocarcinoma: Molecular Heterogeneity and Differences from Squamous Cell Carcinoma.

Yusuke Taira, Wataru Kudaka, Yuko Shimoji, Tomoko Nakamoto, Yoshihisa Arakaki, Takuma Oyama, Akihiro Yoshida, Toshiaki Watanabe, Hina Akamine, Ikuko Komesu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yusuke TairaDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Wataru KudakaDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Yuko ShimojiDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Tomoko NakamotoDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Yoshihisa ArakakiDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Takuma OyamaDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Akihiro YoshidaDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Toshiaki WatanabeDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Hina AkamineDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Ikuko KomesuDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.
Masayuki SekineDepartment of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan.ORCID 0000-0003-0751-6395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment for locally advanced and recurrent cervical cancer has advanced substantially with immune checkpoint inhibitors, induction chemotherapy, bevacizumab, and antibody-drug conjugates. However, subgroup analyses of major phase III trials suggest that cervical adenocarcinoma (AC) may respond differently from squamous cell carcinoma (SCC). Therefore, novel treatment strategies based on the distinct biological characteristics of AC are needed. This review aimed to evaluate the efficacy of current treatments for AC by examining histology-specific subgroup analyses from major clinical trials and to identify potential therapeutic strategies for AC. We also reviewed ongoing AC-focused clinical trials of novel molecularly targeted agents and combination therapies for advanced or recurrent disease. A structured search of PubMed and ClinicalTrials.gov through 1 June 2026, identified studies of advanced or recurrent cervical adenocarcinoma. Randomized trials, prospective studies, and histology-specific subgroup analyses were included, while case reports, preclinical studies, and SCC-only studies were excluded. Survival and response outcomes were extracted, with histology-specific findings considered exploratory. AC exhibits distinct molecular and immunological features compared with SCC, including frequent alterations in

Indexed as

AdenocarcinomaCarcinoma, Squamous CellNeoplasm Recurrence, LocalUterine Cervical NeoplasmsFemaleHumansImmune Checkpoint InhibitorsMolecular Targeted TherapyImmune Checkpoint Inhibitorsantibody–drug conjugatecervical adenocarcinomacervical cancerclinical trialsimmune checkpoint inhibitormolecular-targeted agents

Identifiers

PMID42883892
PMCPMC13664901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.